A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation (2019)
Attributed to:
Precision targeting of mTOR in conventional and MHC class I-restricted anti-tumour CD4+ T cells
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1182/blood-2019-128044
Publication URI: http://dx.doi.org/10.1182/blood-2019-128044
Type: Journal Article/Review
Parent Publication: Blood
Issue: Supplement_1